ClinicalTrials.gov
public full text
Public Domain
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.#1046645
- Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients#917410
- Análisis del impacto de la aparición de síntomas neurológicos leves en pacientes que padecieron una forma leve de COVID-19 (sars-cov2), en relación con pacientes con síntomas similares sin antecedentes de la enfermedad.#1168036
- the Efficacy and Safety of Spirulina Maxima Extract on Improvement of Cognitive Function#967912
- Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study#850873
Record · ID 857424
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive